Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bao Ho

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Asia-Pacific Journal of Clinical Oncology|April 18, 2018
<sup>68</sup> Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancerGeorge Hruby, Thomas Eade, Louise Emmett, et al.
Journal of Medical Internet Research|December 18, 2016
Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary ViewWei Luo, Dinh Phung, Truyen Tran, et al.
The British Journal of Radiology|December 20, 2018
<sup>68</sup>Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgeryRohan Nandurkar, Pimmeke van Leeuwen, Phillip Stricker, et al.
Pharmaceuticals (Basel, Switzerland)|July 27, 2022
<sup>64</sup>Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I TrialKeith Wong, Gemma Sheehan-Dare, Andrew Nguyen, et al.
Journal of Medical Imaging and Radiation Oncology|October 22, 2021
Diagnostic value of <sup>68</sup> Ga-DOTATATE PET-CT imaging for staging of ER<sup>+</sup> /PR<sup>+</sup> HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and <sup>18</sup> F-FDG PET-CT in a prospective pilot trialAndrew Nguyen, Karen Fullard, Gemma Sheehan-Dare, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2018
Prospective, Multisite, International Comparison of <sup>18</sup>F-Fluoromethylcholine PET/CT, Multiparametric MRI, and <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient OutcomesLouise Emmett, Ur Metser, Glenn Bauman, et al.
Clinical Genitourinary Cancer|November 15, 2018
Results of a Prospective Phase 2 Pilot Trial of <sup>177</sup>Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of ProgressionLouise Emmett, Megan Crumbaker, Bao Ho, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 27, 2015
Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted TherapyJoshua J Morigi, Phillip D Stricker, Pim J van Leeuwen, et al.
BJU International|August 4, 2018
Gallium-68-prostate-specific membrane antigen (<sup>68</sup> Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancerPim J van Leeuwen, Maarten Donswijk, Rohan Nandurkar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2017
Treatment Outcomes from <sup>68</sup>Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PETLouise Emmett, Pim J van Leeuwen, Rohan Nandurkar, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Asia-Pacific Journal of Clinical Oncology|April 18, 2018
<sup>68</sup> Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancerGeorge Hruby, Thomas Eade, Louise Emmett, et al.
Journal of Medical Internet Research|December 18, 2016
Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary ViewWei Luo, Dinh Phung, Truyen Tran, et al.
The British Journal of Radiology|December 20, 2018
<sup>68</sup>Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgeryRohan Nandurkar, Pimmeke van Leeuwen, Phillip Stricker, et al.
Pharmaceuticals (Basel, Switzerland)|July 27, 2022
<sup>64</sup>Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I TrialKeith Wong, Gemma Sheehan-Dare, Andrew Nguyen, et al.
Journal of Medical Imaging and Radiation Oncology|October 22, 2021
Diagnostic value of <sup>68</sup> Ga-DOTATATE PET-CT imaging for staging of ER<sup>+</sup> /PR<sup>+</sup> HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and <sup>18</sup> F-FDG PET-CT in a prospective pilot trialAndrew Nguyen, Karen Fullard, Gemma Sheehan-Dare, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2018
Prospective, Multisite, International Comparison of <sup>18</sup>F-Fluoromethylcholine PET/CT, Multiparametric MRI, and <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient OutcomesLouise Emmett, Ur Metser, Glenn Bauman, et al.
Clinical Genitourinary Cancer|November 15, 2018
Results of a Prospective Phase 2 Pilot Trial of <sup>177</sup>Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of ProgressionLouise Emmett, Megan Crumbaker, Bao Ho, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 27, 2015
Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted TherapyJoshua J Morigi, Phillip D Stricker, Pim J van Leeuwen, et al.
BJU International|August 4, 2018
Gallium-68-prostate-specific membrane antigen (<sup>68</sup> Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancerPim J van Leeuwen, Maarten Donswijk, Rohan Nandurkar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2017
Treatment Outcomes from <sup>68</sup>Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PETLouise Emmett, Pim J van Leeuwen, Rohan Nandurkar, et al.
Pageof 7